Overview of hereditary angioedema caused by C1-inhibitor deficiency: Assessment and clinical management

European Annals of Allergy and Clinical Immunology

Volumn 45, Issue 1, 2013, Pages 7-16

  Bork, K ^a   Davis Lorton, M ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Angioedema; C1 inhibitor deficiency; Hereditary angioedema (HAE); Management

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 12; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; KALLIKREIN; OXANDROLONE; PLASMIN; PLASMINOGEN; PREKALLIKREIN; PROTHROMBIN A; STANOZOLOL; TRANEXAMIC ACID;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; CELL SURFACE; CLINICAL ASSESSMENT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FATIGUE; FEVER; HEADACHE; HEREDITARY ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LARYNX EDEMA; MUSCLE SPASM; MYALGIA; NAUSEA; NOSE OBSTRUCTION; POSTURAL HYPERTENSION; REVIEW; TREATMENT OUTCOME; VERTIGO;

COMPLEMENT C1 INACTIVATOR PROTEINS; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84875384643     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
2. Bork L, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks of hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101: 619-27.
3. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-74.
4. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417-29.
5. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147-54.
6. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78.
7. Kalmár L, Hegedüs T, Farkas H, Nagy M, Tordai A. HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 2005; 25: 1-5.
8. Bork K. Recurrent angioedema and the threat of asphyxiation. Dtsch Arztebl Int 2010; 107: 408-14.
9. Caccia S, Castelli R, Maiocchi D, Bergamaschini L, Cugno M. Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagul Fibrinolysis 2011; 22: 571-5.
10. Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64: 254-7.
11. van Geffen M, Cugno M, Lap P, Loof A, Cicardi M, van Heerde W. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012; 167: 472-8.
12. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol 2005; 114: 3-9.
13. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pallacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7.
14. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999; 104: 1321-2.
15. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027-36.
16. Kemp JG, Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review. Allergy Asthma Proc 2009; 30: 493-9.
17. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-54.
18. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114(3 suppl): S51-131.
19. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-15.
20. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 314-20.
21. Zilberberg M, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc 2010; 31: 511-9.
22. Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol 2010; 104: 211-4.
23. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-14.
24. Cicardi M, Agostoni A. Hereditary angioedema [editorial]. N Engl J Med 1996; 334: 1666-7.
25. Frigas E, Park M. Idiopathic recurrent anigoedema. Immunol Allergy Clin North Am 2006; 26: 739-51.
26. Nzeako UC. Diagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective. World J Gastroenterol 2010; 16: 4913-21.
27. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005; 53: 373-88.
28. Weldon D. Differential diagnosis of angioedema. Immunol Allergy Clin North Am 2006; 26: 603-13.
29. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 2006; 26: 669-90.
30. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141(1): 31-5.
31. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Comm 2006; 343: 1286-9.
32. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006; 26: 709-24.
33. Bork K, Gül D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007; 120: 987-92.
34. Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136: 153-8.
35. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999; 15: 21-5.
36. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007; 98: 57-63.
37. McGlinchey PG, Golchin K, McCluskey DR. Life-threatening laryngeal oedema in a pregnant woman with hereditary angioedema. Ulster Med J 2000; 69: 54-7.
38. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98: 383-8.
39. Cicardi M, Bork K, Caballero T, et al, on behalf of the HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-57.
40. Baker J, Riedl M, Banerji A, et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (Cinryze) for treatment or prophylaxis of acute attacks of hereditary angioedema (HAE) in pregnant subjects [abstract]. Ann Allergy Asthma Immunol 2010; 105: A10.
41. Bork K. Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency. Expert Review Clin Immunol 2011; 7(6): 723-33.
42. Craig TJ, Wasserman RL, Levy RJ. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010; 30: 823-9.
43. Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 2010; 152: 44-9.
44. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010; 203: 131.e1-7.
45. Zuraw BL. Hereditary angioedema: a current state-of-the-art review, IV: short-and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 2008; 100(1 suppl 2): S13-8.
46. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008; 63: 751-7.
47. Farkas H, Jakab L, Temesszentandrási G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120: 941-7.
48. Wasserman RL, Levy RJ, Bewtra AK, et al. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol 2011; 106: 62-8.
49. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-22.
50. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-7.
51. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8.
52. De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29: 247-54.
53. Riedl MA, Hurewitz DS, Levy R, Busse PJ, Fitts D, Kalfus I. Nanofiltered C1 esterase inhibitor (human) for treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol 2012; 108: 49-53.
54. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykininreceptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41.
55. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-31.
56. Krause K, Metz M, Zuberbier T, Maurer M, Magerl M. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. J Dtsch Dermatol Ges 2010; 8: 272-4.
57. Kalbitor (ecallantide) prescribing information. Dyax Corporation, Cambridge, MA; February 2012. http://kalbitor.com/hcp/rems/pdf/KalbitorFullPrescribingInformation.pdf Accessed May 15, 2012.
58. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444-8.
59. Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 1960; 53: 739-45
60. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-61.
61. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99: 194-6.
62. Zurlo JJ, Frank MM. The long-tem safety of danazol in women with hereditary angioedema. Fertil Steril 1990; 54: 64-72.
63. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353(9158): 1066-7.
64. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011; 154: 81-8.
65. Zurano BL, Kalfus I. Safety and efficacy of prophylactic manofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012; 125: 938. e1-7.
66. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139: 379-94.
67. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2011; 52: 100-7.
68. Boyle RJ, Nikpour M, Tang MLK. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol 2005; 16: 288-94.
69. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010; 6: 18.
70. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 2011; 112(1): 58-64